CannTrust Partners with Australian Hospital Partner in ALS Clinical Trial

Published: July 11, 2018

CannTrust Partners with Australian Hospital Partner in ALS Clinical Trial

CannTrust Holdings Inc., one of Canada’s leading licensed producers of medical cannabis, announced today that it has partnered with Australia’s Gold Coast University Hospital to conduct a randomized, double-blind, placebo-controlled clinical trial to determine the efficacy of CannTrust cannabidiol (CBD) oil capsules in slowing the disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND). Patient safety and tolerability will also be assessed. The study has received Research Ethics Board approval and Australian Therapeutic Good Administration Acknowledgement for the study drug.

The six-month study will be led by Gold Coast Neurologist, Dr. Arman Sabet, MD. Gold Coast is one of Australia’s leading tertiary referral institutions for ALS management and Dr. Sabet has been involved in many international clinical trials specializing in neuromuscular disorders and stroke.

Dr. Sabet’s research will also analyze the effects of CannTrust CBD oil capsules on study participants’ spasticity, pain, weight loss and quality of life.

“ALS is a fatal disease with no known cure. This study will help advance our understanding of the potential effects of CannTrust’s standardized CBD oil capsules on ALS/MND, both as a disease modifying agent and as a symptomatic treatment and will become the basis for conducting future cannabinoid and ALS clinical trials,” said Dr. Sabet, MD, Senior Staff Specialist, Gold Coast University Hospital.

“The rate of ALS progression is often rapid, creating high levels of disability for patients. People diagnosed with ALS have an average life expectancy of 2.5 years. CannTrust is proud to participate in this important study which aims to help us better understand the potential impact of CannTrust CBD oil capsules on ALS and MND, so that patients might face better outcomes,” said Eric Paul, CEO, CannTrust.

Recent News

View All News Items

Latest Article

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

At any step in the cannabis supply chain, your labeling system should allow for full control and traceability, from seed to sale. Implementing lean principles and labeling best practices across the cannabis supply chain can help you streamline your seed-to-sale labeling process and help you gain control.

Click below to read the full blog and learn how to reduce waste, cut costs, and gain efficiency with cannabis labeling: https://bit.ly/2KwZ5IQ

Read Article